Oppenheimer Gives a Buy Rating to Medtronic

By Ryan Adsit

In a report released today, Steven Lichtman from Oppenheimer reiterated a Buy rating on Medtronic (NYSE: MDT). The company’s shares opened today at $80.33.

According to TipRanks.com, Lichtman is ranked 0 out of 5 stars with an average return of -3.5% and a 53.8% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Integra Lifesciences.

Currently, the analyst consensus on Medtronic is Strong Buy and the average price target is $89.75, representing an 11.7% upside.

In a report issued on April 6, Needham also reiterated a Buy rating on the stock with a $91 price target.

Medtronic’s market cap is currently $109.5B and has a P/E ratio of 28.40. The company has a book value ratio of 2.2274.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.